AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9755260
Drug: Mild systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild systemic cooling (rectal temperature = 35.7 +/- 0.2 degreesC, n = 6)
Trial: 31095995
Drug: KET/FENT (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KET/FENT (three 25 μg fentanyl injections over 1.5 h)
Trial: 31095995
Drug: Ketamine only
RxNorm normalized name: Ketamine only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine only administration
Trial: 29438092
Drug: Parsatuzumab (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parsatuzumab (600 mg) in combination with bevacizumab (15 mg/kg) and carboplatin/paclitaxel
Trial: 29438092
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in combination with bevacizumab (15 mg/kg) and carboplatin/paclitaxel
Trial: 22410113
Drug: Enamel contralateral-antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enamel contralateral-antagonist
Trial: 16305584
Drug: 100 microg
RxNorm normalized name: Digoxin 100 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 microg salbutamol (1 dose)
Trial: 16305584
Drug: 100 microg
RxNorm normalized name: Digoxin 100 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 microg salbutamol (2 doses)
Trial: 16305584
Drug: SLOW inhalation
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SLOW inhalation (20 l min(‐1))
Trial: 16305584
Drug: FAST inhalation
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAST inhalation (60 l min(‐1))
Trial: 16305584
Drug: LATE inhalation
RxNorm normalized name: glycopyrrolate Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LATE inhalation (slow inhalation after 5 s)
Trial: 12079631
Drug: 1.45 microm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.45 microm diode laser with cryogen spray cooling, average power 12 W, treated on three separate occasions 3 weeks apart.
Trial: 12079631
Drug: Cryogen spray
RxNorm normalized name: carbogen
DrugBank: Carbon dioxide (DB09157)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cryogen spray cooling alone, treated on the contralateral sides as control.
Trial: 10442547
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) 400 microg twice daily for 12 weeks
Trial: 10442547
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) 400 microg once daily for 12 weeks
Trial: 10442547
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) 400 microg once daily for a further 12 weeks
Trial: 7778170
Drug: ATG (ATGAM)
RxNorm normalized name: ATGAM
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATG (ATGAM) administered in variable doses to maintain the absolute number of peripheral CD3 T cells at 50-100/microliters (Group 1)
Trial: 7778170
Drug: ATG given
RxNorm normalized name: equine ATG
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATG given at a fixed dose of 15 mg/kg/day (Group 2)
Trial: 7778170
Drug: Group 1
RxNorm normalized name: Chlamydophila psittaci biogroup 1 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1 (variable dosing) vs Group 2 (fixed dosing)
Trial: 2088233
Drug: Doxycycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (100 mg for 14 days)
Trial: 30940694
Drug: Intramuscular nalmefene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular nalmefene (1.5 mg)
Trial: 21570643
Drug: Atorvastatin 20mg
RxNorm normalized name: AMLODIPINE 5MG/ATORVASTATIN 20MG TAB
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20mg
Trial: 21036355
Drug: Atorvastatin in
RxNorm normalized name: Product containing atorvastatin in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin in low cholesterol synthesisers with high absorption
Trial: 17337382
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment using HDAC inhibitors and PPARγ agonists
Trial: 17337382
Drug: PPARγ agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPARγ agonists (thiazolidinediones)
Trial: 10937517
Drug: Thalidomide (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thalidomide (150 mg orally at bedtime)
Trial: 2869616
Drug: Oxprenolol slow
RxNorm normalized name: oxprenolol
DrugBank: Oxprenolol (DB01580)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxprenolol slow release 160 mg b.i.d.
Trial: 6373264
Drug: Oxprenolol slow
RxNorm normalized name: oxprenolol
DrugBank: Oxprenolol (DB01580)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxprenolol slow release 160 mg b.i.d. in patients <65 years
Trial: 6373264
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in patients <65 years continuing medication
Trial: 24989892
Drug: Chemotherapy only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy only (arm A)
Trial: 8683682
Drug: Bacillus Calmette-Guerin
RxNorm normalized name: BACILLUS CALMETTE-GUERIN VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacillus Calmette-Guerin (BCG) instillation (120 mg, weekly for 6 weeks, then monthly for up to 1 year and every 3 months during year 2)
Trial: 8683682
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin C instillation (40 mg, weekly for 6 weeks, then monthly for up to 1 year and every 3 months during year 2)
Trial: 27040557
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) targeting social skills and anxiety
Trial: 21315879
Drug: One-session computer-based
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-session computer-based exposure (CBE) treatment; 27-minute session with nine fear-eliciting spider pictures
Trial: 16930908
Drug: Formulation optimization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation optimization
Trial: 11549629
Drug: Transdermal dihydrotestosterone
RxNorm normalized name: 2α-Methyl-4,5-dihydrotestosterone propionate
DrugBank: Drostanolone propionate (DB14655)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal dihydrotestosterone gel (70 mg daily)
Trial: 7785133
Drug: Antioxidant treatment
RxNorm normalized name: OCTINOXATE 6 g in 100 g / AVOBENZONE 1.7 g in 100 g TOPICAL CREAM [Renewing Antioxidant Treatment SPF 6 GNLD International]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant treatment (10% dibunol liniment and 5% ascorbic acid) injected 2 times a day, combined with 500,000 U of ampicillin for purulent sinusitis; injected once a day without antibiotic for catarrhal sinusitis.
Trial: 7785133
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (4 ml dioxidine in a single dose for catarrhal sinusitis; 500,000 U ampicillin plus hydrocortisone emulsion 2 times a day for purulent sinusitis).
Trial: 3136831
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg and 100 mg doses
Trial: 24035110
Drug: Topical doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical doxycycline hyclate
Trial: 19617207
Drug: Low-dose hCG
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose hCG (200 IU/l daily)
Trial: 19617207
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with rFSH (Puregon) plus a GnRH‐antagonist
Trial: 1856908
Drug: Caffeine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (200 mg)
Trial: 19850691
Drug: MMI+IID (Methimazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMI+IID (Methimazole combined with intrathyroid injection of dexamethasone)
Trial: 17304779
Drug: Ondansetron, 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron, 4 mg intravenously (Control)
Trial: 17304779
Drug: Inhaled isopropyl
RxNorm normalized name: Isopropyl Alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled isopropyl alcohol (IPA)
Trial: 15066931
Drug: +ISO (soy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: +ISO (soy protein drink providing 83 mg/day isoflavones)
Trial: 11755456
Drug: 2 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g/day ethyl eicosapentaenoate (E‐E)
Trial: 11755456
Drug: 4 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g/day ethyl eicosapentaenoate (E‐E)
Trial: 8672379
Drug: Transdermal hyoscine
RxNorm normalized name: HYOSCINE HYDROBROMIDE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal hyoscine
Trial: 27265390
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (GL)
Trial: 23278837
Drug: Oscillating Pressure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oscillating Pressure Infusion (OPI) method
Trial: 21627685
Drug: Grade 1
RxNorm normalized name: SZOSIL Medical-Grade 15-Day Silicone Gel Sheet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grade 1 hypoglycaemia (blood glucose < 4 mmol/l with no associated symptoms)
Trial: 19085723
Drug: Fluvoxamine (50-150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (50-150 mg)
Trial: 11123495
Drug: Testosterone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone (200 mg testosterone enanthanate, intramuscularly every 2 weeks)
Trial: 10968046
Drug: 1.2 g
RxNorm normalized name: Humidifier 1.2 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 g of Augmentin intravenously
Trial: 31610337
Drug: Beclomethasone suppositories
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone suppositories (3mg, n=42)
Trial: 25038357
Drug: tesamorelin, 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tesamorelin, 2 mg, subcutaneously daily for 6 months
Trial: 23233650
Drug: 1500 mg
RxNorm normalized name: inulin 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg lapatinib for 28-42 days before surgery
Trial: 2887941
Drug: captopril 25
RxNorm normalized name: captopril 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: captopril 25 mg twice daily
Trial: 2887941
Drug: atenolol 100
RxNorm normalized name: atenolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atenolol 100 mg once daily
Trial: 2887941
Drug: pindolol 10
RxNorm normalized name: pindolol 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pindolol 10 mg twice daily
Trial: 18377400
Drug: Midazolam (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (10 mg increments, i.m. or i.v., at 10 min intervals, up to four doses)
Trial: 12719802
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (0.5 mg/ml) perfusion before implantation
Trial: 12719802
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Euro-Collins solution without AA)
Trial: 10362452
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of calcium pyruvate (60%) and creatine (40%) (Group COM, n = 11)
Trial: 2126394
Drug: NORPLANT six
RxNorm normalized name: Norplant 3-oxime
DrugBank: Norelgestromin (DB06713)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NORPLANT six capsule system
Trial: 25431052
Drug: Baricitinib 4
RxNorm normalized name: baricitinib 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baricitinib 4 mg and 8 mg
Trial: 28376282
Drug: Relaxation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation therapy (RT)
Trial: 18778905
Drug: Oxygen-ozone combined
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen-ozone combined with collagenase injection
Trial: 16917950
Drug: methylphenidate (OROS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: methylphenidate (OROS and immediate release preparations)
Trial: 1676367
Drug: Enalapril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (5 mg)
Trial: 3327150
Drug: Multiple dose
RxNorm normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dose of cotrimoxazole
Trial: 12890370
Drug: Lactated Ringer's
RxNorm normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lactated Ringer's solution (LRS), equal to three times the EBL
Trial: 12890370
Drug: 6% hydroxyethyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% hydroxyethyl starch (HES) solution, equal to estimated blood loss (EBL)
Trial: 10523748
Drug: Beta-carotene arm
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene arm (treatment)
Trial: 1764952
Drug: Ofloxacin tablet
RxNorm normalized name: Ofloxacin Tablets
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ofloxacin tablet (200 mg)
Trial: 1764952
Drug: Ofloxacin tablet
RxNorm normalized name: Ofloxacin Tablets
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ofloxacin tablet (300 mg)
Trial: 30063901
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection (0.9% saline)
Trial: 30063901
Drug: Depot medroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depot medroxyprogesterone acetate injection
Trial: 17312208
Drug: Sugammadex 8.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex 8.0 mg/kg
Trial: 25923435
Drug: Sugammadex 4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex 4.0 mg/kg
Trial: 19933538
Drug: Sugammadex (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex (various doses)
Trial: 27756322
Drug: Postoperative oral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative oral elemental diet (Elental®, 300 kcal/day)
Trial: 16152823
Drug: Fuzheng Jiangnian
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fuzheng Jiangnian Capsule (FZJN)
Trial: 16152823
Drug: Compound Salviae
RxNorm normalized name: Salvia sclarea seed oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound Salviae droplet pill (CSDP)
Trial: 31914451
Drug: Aspirin (ASP)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (ASP)
Trial: 8993243
Drug: Low-dose aprotinin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose aprotinin (2 x 10(6) KIU or 280 mg in the pump)
Trial: 31142943
Drug: 1% Vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% Vitamin K cream
Trial: 31142943
Drug: 1% phenytoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% phenytoin cream
Trial: 9756781
Drug: Pleconaril oral
RxNorm normalized name: pleconaril
DrugBank: Pleconaril (DB05105)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pleconaril oral solution (200 mg) coadministered with a standard English breakfast
Trial: 9756781
Drug: Pleconaril oral
RxNorm normalized name: pleconaril
DrugBank: Pleconaril (DB05105)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pleconaril oral solution (200 mg) in fasting state
Trial: 9756781
Drug: Pleconaril oral
RxNorm normalized name: pleconaril
DrugBank: Pleconaril (DB05105)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pleconaril oral solution (200 mg)
Trial: 3278595
Drug: Pure alcohol
RxNorm normalized name: ISOPROPYL ALCOHOL 70 mL in 100 mL TOPICAL LIQUID [Biopure alcohol prep pads 70 isopropyl]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pure alcohol injection
Trial: 31049139
Drug: Cordyceps militaris
RxNorm normalized name: CORDYCEPS MILITARIS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cordyceps militaris (COG, 100 mg daily)
Trial: 25350981
Drug: Droxidopa (100-600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droxidopa (100-600 mg, 3× daily)
Trial: 21602542
Drug: Fluctuations in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluctuations in twice‐daily peak expiratory flow (PEF) over 6 months
Trial: 18581891
Drug: Subcutaneous injection
RxNorm normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of salmon calcitonin (50 U) three times a week for 18 months
Trial: 18581891
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of calcium carbonate 1500 mg tid and rocaltrol 0.25 microg qn for 18 months (Control)
Trial: 16344320
Drug: FDR gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDR gemcitabine 1,000 mg/m2 at 10 mg/m2/min with cisplatin 20 mg/m2 on days 1 and 8 of a 21-day cycle
Trial: 10800798
Drug: heparin-coated circuit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: heparin-coated circuit with aprotinin (HCO-A)
Trial: 10800798
Drug: heparin-coated circuit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: heparin-coated circuit without aprotinin (HCO)
Trial: 18672641
Drug: Quinaril (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinaril (20 mg quinapril hydrochloride)
Trial: 16091254
Drug: Immune-based therapies
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune-based therapies as an adjunct to antiretroviral treatment
Trial: 16091254
Drug: Immune-based therapies
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune-based therapies
Trial: 16091254
Drug: Immunomodulating therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunomodulating therapies
Trial: 10575530
Drug: Reteplase (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reteplase (administered in bolus injections)
Trial: 7677218
Drug: Paromomycin ointment
DrugBank: Paromomycin (DB01421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paromomycin ointment applied twice a day from day 1 through day 14
Trial: 7677218
Drug: Paromomycin ointment
DrugBank: Paromomycin (DB01421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paromomycin ointment
Trial: 7677218
Drug: Paromomycin ointment
DrugBank: Paromomycin (DB01421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paromomycin ointment and Placebo
Trial: 382379
Drug: Antibiotics +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics + Placebo
Trial: 382379
Drug: Antibiotics +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics + Pseudoephedrine
Trial: 382379
Drug: Antibiotics +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics + Triprolidine
Trial: 31821157
Drug: β-hydroxybutyrate infusion
RxNorm normalized name: 4-hydroxybutyric acid
DrugBank: gamma-Hydroxybutyric acid (DB01440)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-hydroxybutyrate infusion
Trial: 30420448
Drug: Ipilimumab 10
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab 10 mg/kg + High-Dose Interferon-α2b (HDI)
Trial: 23478743
Drug: Aliskiren (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren (150 mg daily, increased to 300 mg as tolerated)
Trial: 18355658
Drug: Amlodipine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine treatment
Trial: 16736344
Drug: Aprotinin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin (1 x 10(6) KIU loading dose before surgery and 5 x 10(5) KIU/h during surgery, gross dose: 2.5 x 10(6) KIU, n=36)
Trial: 16736344
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution (control, n=40)
Trial: 27138794
Drug: Raloxifene (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene (120 mg per day orally)
Trial: 1959195
Drug: Nisoldipine 10
RxNorm normalized name: nisoldipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nisoldipine 10 mg twice daily
Trial: 6337605
Drug: Dazoxiben (thromboxane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dazoxiben (thromboxane synthetase inhibitor)
Trial: 31911146
Drug: Double-dose inactivated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-dose inactivated influenza vaccine
Trial: 26269098
Drug: AVATAR therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVATAR therapy (7 sessions)
Trial: 21974746
Drug: Six weekly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Six weekly sessions of motivational interviewing and cognitive behavioral therapy initiated approximately six weeks prior to release from prison.